Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

JR. Santos, A. Cozzi-Lepri, A. Phillips, S. De Wit, C. Pedersen, P. Reiss, A. Blaxhult, A. Lazzarin, M. Sluzhynska, C. Orkin, C. Duvivier, J. Bogner, P. Gargalianos-Kakolyris, P. Schmid, G. Hassoun, I. Khromova, M. Beniowski, V. Hadziosmanovic,...

. 2018 ; 19 (5) : 324-338. [pub] 20180201

Language English Country England, Great Britain

Document type Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028595
E-resources Online Full text

NLK Free Medical Journals from 1999 to 2 years ago
Medline Complete (EBSCOhost) from 1999-10-01 to 1 year ago
Wiley Free Content from 1999 to 2 years ago

Links

PubMed 29388732
DOI 10.1111/hiv.12581
Knihovny.cz E-resources

OBJECTIVES: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens. METHODS: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches. RESULTS: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART. CONCLUSIONS: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028595
003      
CZ-PrNML
005      
20190822124713.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/hiv.12581 $2 doi
035    __
$a (PubMed)29388732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Santos, J R $u Fight Against AIDS Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain.
245    10
$a Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe / $c JR. Santos, A. Cozzi-Lepri, A. Phillips, S. De Wit, C. Pedersen, P. Reiss, A. Blaxhult, A. Lazzarin, M. Sluzhynska, C. Orkin, C. Duvivier, J. Bogner, P. Gargalianos-Kakolyris, P. Schmid, G. Hassoun, I. Khromova, M. Beniowski, V. Hadziosmanovic, D. Sedlacek, R. Paredes, JD. Lundgren, EuroSIDA study group,
520    9_
$a OBJECTIVES: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens. METHODS: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches. RESULTS: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART. CONCLUSIONS: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x terapeutické užití $7 D019380
650    _2
$a vysoce aktivní antiretrovirová terapie $x metody $7 D023241
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cozzi-Lepri, A $u Royal Free and University College, London, UK.
700    1_
$a Phillips, A $u Royal Free and University College, London, UK.
700    1_
$a De Wit, S $u Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium.
700    1_
$a Pedersen, C $u Odense University Hospital, Odense, Denmark.
700    1_
$a Reiss, P $u Academic Medical Center, Amsterdam, the Netherlands.
700    1_
$a Blaxhult, A $u Karolinska Institute, Venhälsan, Stockholm, Sweden.
700    1_
$a Lazzarin, A $u San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Sluzhynska, M $u Lviv Regional HIV/AIDS Prevention and Control Centre, Kiev, Ukraine.
700    1_
$a Orkin, C $u Royal London Hospital, London, UK.
700    1_
$a Duvivier, C $u Hôpital Necker-Enfants Malades, Paris, France.
700    1_
$a Bogner, J $u Medizinische Poliklinik, Munchen, Germany.
700    1_
$a Gargalianos-Kakolyris, P $u The General Hospital of Athens "G. Gennimatas", Athens, Greece.
700    1_
$a Schmid, P $u Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Hassoun, G $u Rambam Health Care Campus, Haifa, Israel.
700    1_
$a Khromova, I $u Centre for HIV/AIDS and Infectious Diseases, Moscow, Russia.
700    1_
$a Beniowski, M $u Szpital Specjalistyczny, Chorzow, Poland.
700    1_
$a Hadziosmanovic, V $u Klinicki Centar Univerziteta Sarajevo (KCUS), Sarajevo, Bosnia & Herzegovina.
700    1_
$a Sedlacek, D $u Charles University Hospital, Plzen, Czech Republic.
700    1_
$a Paredes, R $u Fight Against AIDS Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain. IrsiCaixa AIDS Research Institute, Barcelona, Spain. Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain.
700    1_
$a Lundgren, J D $u Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
710    2_
$a EuroSIDA study group
773    0_
$w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 19, č. 5 (2018), s. 324-338
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29388732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822124952 $b ABA008
999    __
$a ok $b bmc $g 1433744 $s 1067055
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 5 $d 324-338 $e 20180201 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options